These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

883 related articles for article (PubMed ID: 25477054)

  • 1. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
    Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
    Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients.
    Charles P; Néel A; Tieulié N; Hot A; Pugnet G; Decaux O; Marie I; Khellaf M; Kahn JE; Karras A; Ziza JM; Deligny C; Tchérakian C; Guillevin L;
    Rheumatology (Oxford); 2014 Mar; 53(3):532-9. PubMed ID: 24282319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
    Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR
    Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre.
    Besada E; Koldingsnes W; Nossent JC
    Rheumatology (Oxford); 2013 Nov; 52(11):2041-7. PubMed ID: 23934313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
    Timlin H; Lee SM; Manno RL; Seo P; Geetha D
    Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients.
    Calich AL; Puéchal X; Pugnet G; London J; Terrier B; Charles P; Mouthon L; Guillevin L;
    J Autoimmun; 2014 May; 50():135-41. PubMed ID: 24703438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
    Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
    Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center.
    Cartin-Ceba R; Golbin JM; Keogh KA; Peikert T; Sánchez-Menéndez M; Ytterberg SR; Fervenza FC; Specks U
    Arthritis Rheum; 2012 Nov; 64(11):3770-8. PubMed ID: 22730028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models.
    McClure ME; Zhu Y; Smith RM; Gopaluni S; Tieu J; Pope T; Kristensen KE; Jayne DRW; Barrett J; Jones RB
    Rheumatology (Oxford); 2021 Mar; 60(3):1491-1501. PubMed ID: 33141217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
    Thiel J; Hässler F; Salzer U; Voll RE; Venhoff N
    Arthritis Res Ther; 2013 Sep; 15(5):R133. PubMed ID: 24286362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of rituximab trials on the treatment of ANCA-associated vasculitis.
    Alberici F; Jayne DR
    Nephrol Dial Transplant; 2014 Jun; 29(6):1151-9. PubMed ID: 24126571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-dose rituximab for remission induction and maintenance therapy in ANCA-associated vasculitis: a retrospective analysis of 17 patients.
    Moog P; Probst M; Kuechle C; Hauser C; Heemann U; Thuermel K
    Scand J Rheumatol; 2014; 43(6):519-23. PubMed ID: 25179776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis?
    Kallenberg CG
    Curr Opin Rheumatol; 2014 May; 26(3):292-8. PubMed ID: 24646946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
    Charles P; Terrier B; Perrodeau É; Cohen P; Faguer S; Huart A; Hamidou M; Agard C; Bonnotte B; Samson M; Karras A; Jourde-Chiche N; Lifermann F; Gobert P; Hanrotel-Saliou C; Godmer P; Martin-Silva N; Pugnet G; Matignon M; Aumaitre O; Viallard JF; Maurier F; Meaux-Ruault N; Rivière S; Sibilia J; Puéchal X; Ravaud P; Mouthon L; Guillevin L;
    Ann Rheum Dis; 2018 Aug; 77(8):1143-1149. PubMed ID: 29695500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.
    Thiel J; Rizzi M; Engesser M; Dufner AK; Troilo A; Lorenzetti R; Voll RE; Venhoff N
    Arthritis Res Ther; 2017 May; 19(1):101. PubMed ID: 28521808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID).
    Roll P; Ostermeier E; Haubitz M; Lovric S; Unger L; Holle J; Kötter I; Henes JC; Bergner R; Rubbert-Roth A; Specker C; Schulze-Koops H; Müller-Ladner U; Fleck M; Burmester GR; Hiepe F; Heitmann S; Aringer M; Fischer-Betz R; Dörner T; Tony HP
    J Rheumatol; 2012 Nov; 39(11):2153-6. PubMed ID: 22984269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis.
    Besada E; Koldingsnes W; Nossent JC
    Rheumatology (Oxford); 2014 Oct; 53(10):1818-24. PubMed ID: 24831059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
    Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
    J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The "4 plus 2" rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study.
    Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Radin M; Fenoglio R; Baldovino S; Menegatti E
    Oncotarget; 2017 Aug; 8(32):52072-52077. PubMed ID: 28881714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters.
    Chocova Z; Hruskova Z; Mareckova H; Svobodova B; Duskova D; Bednarova V; Jancova E; Rysava R; Tesar V
    Clin Rheumatol; 2015 Jan; 34(1):107-15. PubMed ID: 25388644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.